Egbert F. Smit

Egbert F. Smit, MD, PhD, is Professor of Pulmonary Oncology and Head of Thoracic Oncology at the Netherlands Cancer Institute (NKI-AVL) in Amsterdam, one of Europe's leading cancer centers. He is a co-principal investigator of the VISION trial evaluating tepotinib in MET exon 14 skipping-mutated NSCLC, which led to the FDA approval of tepotinib in this molecularly defined population in 2021. MET exon 14 skipping mutations occur in approximately 3–4% of NSCLC and disproportionately affect older patients with sarcomatoid histology; tepotinib's durable responses and favorable tolerability in this population established it as the preferred MET-targeted option for many clinicians. Smit also contributed to the GEOMETRY mono-1 trial establishing capmatinib in MET-exon-14-skipping NSCLC, and has published translational studies on mechanisms of primary and secondary resistance to MET inhibitors including the emergence of MET amplification, Y1230 kinase domain mutations, and bypass signaling through EGFR and KRAS. Beyond MET, Smit has broad expertise in thoracic oncology clinical trial design and has contributed to European studies on EGFR-targeted therapies, immunotherapy in elderly and performance status-compromised patients, and the integration of circulating tumor DNA in NSCLC monitoring. His center is one of the most active thoracic oncology clinical trial sites in the Netherlands.